Andrés Digenio

3.9k total citations · 3 hit papers
60 papers, 2.9k citations indexed

About

Andrés Digenio is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Andrés Digenio has authored 60 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Endocrinology, Diabetes and Metabolism, 28 papers in Cardiology and Cardiovascular Medicine and 17 papers in Surgery. Recurrent topics in Andrés Digenio's work include Diabetes Treatment and Management (18 papers), Diabetes Management and Research (17 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (16 papers). Andrés Digenio is often cited by papers focused on Diabetes Treatment and Management (18 papers), Diabetes Management and Research (17 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (16 papers). Andrés Digenio collaborates with scholars based in United States, South Africa and Canada. Andrés Digenio's co-authors include James P. Mancuso, Daniel J. Rader, Margaret E. Brousseau, Megan L. Wolfe, Ernst J. Schaefer, Joseph L. Witztum, LeAnne T. Bloedon, Ronald W. Clark, Veronica J. Alexander and Sotirios Tsimikas and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and Journal of the American College of Cardiology.

In The Last Decade

Andrés Digenio

59 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol

2004 574 citations Margaret E. Brousseau, Ernst J. Schaefer et al. New England Journal of Medicine profile →
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

2017 454 citations Mark J. Graham, Richard Lee et al. New England Journal of Medicine profile →
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

2019 416 citations Joseph L. Witztum, Daniel Gaudet et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrés Digenio United States	19	1.6k	1.4k	1.2k	644	589	60	2.9k
Claude Gagné Canada	34	1.9k 1.1×	2.6k 1.8×	1.1k 1.0×	463 0.7×	858 1.5×	77	4.0k
Angelo B. Cefalù Italy	26	896 0.5×	1.1k 0.8×	864 0.7×	411 0.6×	384 0.7×	129	2.5k
Katalin V. Horvath United States	25	1.5k 0.9×	1.6k 1.1×	452 0.4×	379 0.6×	544 0.9×	47	2.5k
Pedro Mata Spain	36	1.0k 0.6×	2.7k 1.8×	830 0.7×	580 0.9×	934 1.6×	119	4.0k
Amanda J. Hooper Australia	26	740 0.4×	1.5k 1.1×	636 0.5×	391 0.6×	432 0.7×	107	2.3k
Rodrigo Alonso Spain	33	808 0.5×	2.0k 1.4×	722 0.6×	501 0.8×	685 1.2×	107	3.1k
Ulrich Julius Germany	28	1.5k 0.9×	1.5k 1.0×	735 0.6×	548 0.9×	257 0.4×	173	3.6k
Núria Plana Spain	29	859 0.5×	1.4k 1.0×	689 0.6×	726 1.1×	461 0.8×	161	2.9k
Christian M. Madsen Denmark	25	842 0.5×	1.5k 1.1×	695 0.6×	263 0.4×	420 0.7×	50	2.3k
Teik Chye Ooi Canada	27	1.0k 0.6×	1.2k 0.8×	633 0.5×	361 0.6×	309 0.5×	79	2.4k

Countries citing papers authored by Andrés Digenio

Since Specialization

Citations

This map shows the geographic impact of Andrés Digenio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrés Digenio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrés Digenio more than expected).

Fields of papers citing papers by Andrés Digenio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrés Digenio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrés Digenio. The network helps show where Andrés Digenio may publish in the future.

Co-authorship network of co-authors of Andrés Digenio

This figure shows the co-authorship network connecting the top 25 collaborators of Andrés Digenio. A scholar is included among the top collaborators of Andrés Digenio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrés Digenio. Andrés Digenio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Dea, Louis, James E. MacDougall, Veronica J. Alexander, et al.. (2019). Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. Journal of the Endocrine Society. 3(12). 2397–2410. 42 indexed citations

Alexander, Veronica J., Andrés Digenio, Shuting Xia, et al.. (2018). INHIBITION OF APOLIPOPROTEIN C-III WITH GALNAC CONJUGATED ANTISENSE DRUG POTENTLY LOWERS FASTING SERUM APOLIPOPROTEIN C-III AND TRIGLYCERIDE LEVELS IN HEALTHY VOLUNTEERS WITH ELEVATED TRIGLYCERIDES. Journal of the American College of Cardiology. 71(11). A1724–A1724. 13 indexed citations

Blom, Dirk, Louis O’Dea, Andrés Digenio, et al.. (2018). Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study. Journal of clinical lipidology. 12(5). 1234–1243.e5. 58 indexed citations

Hegele, Robert A., Amanda J. Berberich, Matthew R. Ban, et al.. (2018). Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. Journal of clinical lipidology. 12(4). 920–927.e4. 112 indexed citations

Graham, Mark J., Richard Lee, Teresa Brandt, et al.. (2017). Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. New England Journal of Medicine. 377(3). 222–232. 454 indexed citations breakdown →

Umpierrez, Guillermo E., David N. O’Neal, Andrés Digenio, et al.. (2017). Lixisenatide reduces glycaemic variability in insulin‐treated patients with type 2 diabetes. Diabetes Obesity and Metabolism. 19(9). 1317–1321. 10 indexed citations

Yang, Xiaohong, Sang Rok Lee, Yun-Seok Choi, et al.. (2016). Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. Journal of Lipid Research. 57(4). 706–713. 81 indexed citations

Inzucchi, Silvio E., Guillermo E. Umpierrez, Andrés Digenio, Rong Zhou, & Boris Kovatchev. (2015). How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes?. Diabetes Research and Clinical Practice. 108(1). 179–186. 18 indexed citations

Digenio, Andrés, Sudeep Karve, Sean D. Candrilli, & Mehul Dalal. (2014). Prandial Insulin versus Glucagon-Like Peptide-1 Added to Basal Insulin: Comparative Effectiveness in the Community Practice Setting. Postgraduate Medicine. 126(6). 49–59. 2 indexed citations

10.

Dalal, Mehul, Lin Xie, Onur Başer, & Andrés Digenio. (2014). Adding Rapid-Acting Insulin or Glp-1 Receptor Agonist to Basal Insulin: Outcomes in A Community Setting. Endocrine Practice. 21(1). 68–76. 17 indexed citations

11.

Pandya, Naushira, Andrés Digenio, Ling Gao, & Meenakshi Patel. (2013). Efficacy and Safety of Insulin Glargine Compared to Other Interventions in Younger and Older Adults: A Pooled Analysis of Nine Open-Label, Randomized Controlled Trials in Patients with Type 2 Diabetes. Drugs & Aging. 30(6). 429–438. 18 indexed citations

12.

Munshi, Medha, Naushira Pandya, Guillermo E. Umpierrez, et al.. (2013). Contributions of Basal and Prandial Hyperglycemia to Total Hyperglycemia in Older and Younger Adults with Type 2 Diabetes Mellitus. Journal of the American Geriatrics Society. 61(4). 535–541. 35 indexed citations

13.

Chaudhuri, Ajay, Julio Rosenstock, Andrés Digenio, et al.. (2011). Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient‐level pooled analysis. Diabetes/Metabolism Research and Reviews. 28(3). 258–267. 14 indexed citations

14.

Brousseau, Margaret E., John S. Millar, Margaret R. Diffenderfer, et al.. (2009). Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism. Journal of Lipid Research. 50(7). 1456–1462. 14 indexed citations

15.

Maron, David J., et al.. (2008). Health-Risk Appraisal With or Without Disease Management for Worksite Cardiovascular Risk Reduction. The Journal of Cardiovascular Nursing. 23(6). 513–518. 18 indexed citations

16.

Brousseau, Margaret E., Ernst J. Schaefer, Megan L. Wolfe, et al.. (2004). Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol. New England Journal of Medicine. 350(15). 1505–1515. 574 indexed citations breakdown →

17.

Terra, Steven G., Robert A. Blum, Greg C. G. Wei, et al.. (2004). Evaluation of Methods for Improving Precision of Blood Pressure Measurements in Phase I Clinical Trials. The Journal of Clinical Pharmacology. 44(5). 457–463. 9 indexed citations

18.

Digenio, Andrés, et al.. (1999). Effect of myocardial ischaemia on left ventricular function and adaptability to exercise training. Medicine & Science in Sports & Exercise. 31(8). 1094–1101. 9 indexed citations

19.

Digenio, Andrés, et al.. (1997). Predictors of Exercise Capacity and Adaptability to Training in Patients With Coronary Artery Disease. Journal of Cardiopulmonary Rehabilitation. 17(2). 110–120. 12 indexed citations

20.

Digenio, Andrés, et al.. (1989). Left ventricular function during sepsis. Critical Care Medicine. 17(4). 323–327. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact